小児がん患者におけるオララツマブ単剤療法および標準化学療法との併用療法に関する研究

基本情報

NCT ID

NCT02677116

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

68

治験依頼者名

Eli Lilly and Company

概要

The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has three parts. In the first two parts, a specific dose of olaratumab will be given in 21 day cycles, followed by one of three standard chemotherapy regimens. In the third part, a specific dose of olaratumab will be given with one of three standard chemotherapy regimens in 21 day cycles. Participants will only enroll in one part.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)